Literature DB >> 86103

Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension.

I M Stewart.   

Abstract

In order to examine the widely held belief that the aim of antihypertensive therapy should be to restore "normality," the relative risk of myocardial infarction and sudden death was related to the extent of pressure reduction in a survey of 169 patients with uncomplicated essential hypertension followed-up under treatment over a mean period of 6.25 years. Apart from the effects of the hypotensive agents, there were no statistically significant differences in coronary heart-disease (C.H.D.) risk factors between the patients who had and those who did not have an infarction. Overall average values for final diastolic pressure (F.D.P.), as last recorded before the end of the study, were almost the same in the two groups. But the relative risk of myocardial infarction in the patients with F.D.P. reduced to less than 90 mm Hg was more than five times that in the patients with F.D.P. 100--109 mm Hg (P less than 0.01), while in those who had developed infarcts with F.D.P.S of less then or equal to 90 mmHg the pressure falls were all markedly greater than in unaffected controls matched for C.H.D. risk factors that included form of treatment, age, sex, and established pre-treatment diastolic pressure (E.D.P.). Thus it would seem that, in severe middle-aged hypertensives, attempts at "normalisation" of high blood-pressure may precipitate as many infarctions as it prevents. Other cardiovascular complications did not exceed the incidence expected during treatment. The findings suggest that the blood-pressure in such patients should seldom be reduced by more than 22% or to diastolic levels less than 104--110 mm Hg.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 86103     DOI: 10.1016/s0140-6736(79)91274-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  52 in total

Review 1.  The j-point phenomenon in aggressive therapy of hypertension: new insights.

Authors:  Gurusher S Panjrath; Sameer Chaudhari; Franz H Messerli
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

2.  On redefining hypertension.

Authors:  Michel Accad; Herbert L Fred
Journal:  Tex Heart Inst J       Date:  2010

Review 3.  The optimal blood pressure target for patients with coronary artery disease.

Authors:  Paolo Verdecchia; Fabio Angeli; Claudio Cavallini; Giovanni Mazzotta; Marta Garofoli; Paola Martire; Gianpaolo Reboldi
Journal:  Curr Cardiol Rep       Date:  2010-07       Impact factor: 2.931

Review 4.  Hypertension.

Authors:  G W Ching; D G Beevers
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

5.  Mild hypertension-where shall treatment begin?

Authors:  D W Feigal; S B Hulley
Journal:  West J Med       Date:  1984-10

6.  Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations : A joint scientific statement from the Austrian Society of Cardiology and the Austrian Society of Hypertension.

Authors:  Thomas Weber; Irene Lang; Robert Zweiker; Sabine Horn; Rene R Wenzel; Bruno Watschinger; Jörg Slany; Bernd Eber; Franz Xaver Roithinger; Bernhard Metzler
Journal:  Wien Klin Wochenschr       Date:  2016-06-09       Impact factor: 1.704

7.  Current status of aggressive blood pressure control.

Authors:  Steven G Chrysant
Journal:  World J Cardiol       Date:  2011-03-26

Review 8.  The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease.

Authors:  Yogini Ratnasabapathy; Carlene M M Lawes; Craig S Anderson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 9.  Oscillating blood pressure therapeutic target in type 2 diabetes patients with hypertension.

Authors:  Aurel T Tankeu; Jean Jacques N Noubiap
Journal:  Ann Transl Med       Date:  2016-11

Review 10.  The J-curve in hypertension.

Authors:  John Cruickshank
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.